Shire Pharmaceuticals hopes to strengthen its ADHD portfolio and establish itself in the global gastrointestinal market with a number of …
AstraZeneca has made a key appointment to its global PR for its statin brand Crestor.Ben Strutt spent six years as …
Roche has raised its full-year sales forecast after strong first quarter results saw the Swiss company outperform a number of …
The monoclonal antibody market will treble in size to $30 billion by 2010, according to a report by analysts Datamonitor.Datamonitor …
A new treatment for the rare and difficult to treat condition of chronic iron overload has been filed by Novartis …
GlaxoSmithKline's Requip has become the first medicine to receive US approval for the treatment of restless legs syndrome (RLS), after …
Pfizer will cut costs worth $4 billion over the next three years in an attempt to return to double-digit earnings …
1) Stay loyal to the core brand message and never undermine itIt may have seemed a good idea at the …
Sales forces in the pharmaceutical industry account for around 75% of marketing budgets, and are coming under increasing pressure to …
Raymond Gilmartin has stood down as chief executive and chairman of Merck, drawing a line under long-running uncertainty regarding the …
GlaxoSmithKline will acquire a Seattle-based biotech that manufactures a key component in many of the candidates in its vaccine pipeline, …
AstraZeneca's Crestor has achieved blockbuster status, despite continuing concerns over its safety, registering sales of over $1 billion for the …
Lilly has gained US marketing approval for Byetta, the first in a new class of type II diabetes treatments derived …
AstraZeneca has received a boost from its phase III drug Cerovive, with clinical trial data showing the treatment can reduce …
Brands are all about 'adding value'. To provide this value to our target customers we need to ensure we have …
Outsourcing as an integral element of a business strategy has waxed and waned in popularity and acceptability over the last …
Launching a new product into a therapeutic area dominated by a 'gold standard' doctors' favourite is a tough task but …